Redeye significantly raises its Base Case for AroCell, given fundamental changes to the case following recent FDA filing in combination with close discussions with management. The company is transitioning to a more commercially oriented business with anticipated key activities in the coming 6-9 months. At a current market capitalization of roughly SEK 130m, we see great upside in the stock on all horizons.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se